



## EVIDENCE MAPPER: A NEW PLATFORM FOR SYSTEMATIC REVIEWS AND MAPPING EVIDENCE



*"Designed by the people who do systematic reviews, our platform makes screening and reconciliation much easier and more efficient, saving us time and reducing errors."*

**Alison Martin, Director**

### Key messages

**The Evidence Mapper is now available for subscribers.**

Our popular platform is now available to other consultancies, pharmaceutical and biotech companies, academic centres and healthcare organisations.

**The Evidence Mapper makes it easier for clients to drill down to find the papers on a specific topic.**

Our clients get rapid access to up-to-date evidence and can easily drill down to find papers on their topic of interest.

**Subscribers can use the Evidence Mapper platform to screen abstracts as well as develop Maps.**

The expanded platform, designed by our in-house researchers who conduct systematic reviews, provides an efficient way of screening abstracts and reconciling conflicts that is ergonomic and easy to use, saving us time and making the process more accurate.

**Indexing abstracts within an Evidence Map is an efficient way of shortlisting papers and drilling down into the evidence.**

The user-friendly interface and in-built AI-inspired classifiers make indexing the content quick and easy.

**Our consultancy still offers bespoke Evidence Maps for clients who don't have the resources to develop their own.**

We are still very happy to develop Maps for clients as part of a systematic, targeted, or rapid review project.

## **The Evidence Mapper is now available for subscribers**

Until now, Crystallise has been the only organisation able to develop Evidence Maps for our clients using this platform. We have now expanded the platform to be available as a subscription-based product, so your organization can develop your own Maps.

*"We know that some clients would like to be able to develop their own Maps, and other consultancies would like to be able to use the platform for their clients without involving us."*

## **The Evidence Mapper makes it easier for clients to drill down and find papers on a specific topic**

Clients have their own secure domain, where they control who can access their Maps. They can't change the content and how it is indexed, but they can view their own Maps and drill down to see the citations reporting each outcome. These citations can then be downloaded as a .csv file with the details of the publication and its tags for further analysis, or a .ris file of the relevant citations, to incorporate into citation manager software. Other files, such as the report and slide deck associated with the project, or PDF files of key full-text publications, can also be uploaded by the client to the Resources page of each Map.

- The Map will automatically show you the tags for two of the fields – just change the field name(s) to see a different display.
- You can now sort tags alphabetically A to Z and Z to A.
- You can select to focus the Map either on content indexed with a specific tag in a third field, or to exclude papers with a specific tag.
- When you export the details of a Map as a .csv file, you can choose whether to see individual tags or just groups of tags within each field.

Evidence Mapper

[RETURN TO ADMIN](#)

Mental health benefits of chocolate
[Home](#)
[Map](#)
[Abbreviations](#)
[Key](#)
[Search](#)
[Resources](#)

First category \*  
  
The first category to be included in the map will be shown as rows

Secondary category  
  
The second category to be included in the map will be shown as columns

Filter by tag  
  
Reduce the citations to focus on specific tags

Filter by tag

Order by

Filter out by tag  
  
Reduce the citations by filtering papers based on specific tags

Filter out by tag

[help](#)

All papers (includes unpublished)

Please change 'First category' OR 'Second Category' to change result set

	Association with disease	Biomarker changes	Disease improvement	Disease prevention	Disease progression	Mortality	Quality of life	Unclear	unallocated
Clinical trial	0	1	0	0	0	0	0	0	0
Cross-sectional	2	0	1	0	0	0	0	0	0
Narrative review	0	3	1	3	0	1	0	0	0
Pooled analysis	0	0	1	0	0	0	0	0	0
Prospective observational	1	0	0	1	0	0	1	0	0
RCT	0	1	3	0	0	0	0	0	0
Retrospective observational	1	0	1	0	1	1	0	0	0
SLR	0	0	1	0	0	0	0	0	0
Unclear	0	0	0	0	0	0	0	3	0
unallocated	0	0	0	0	0	0	0	0	10

☒ This symbol indicates that new papers have been added to the field

## Subscribers can use the Evidence Mapper platform to screen abstracts as well as develop Maps

*"Designed by the people who do systematic reviews, our platform makes screening and reconciliation much easier and more efficient, saving us time and reducing errors."*

We know our clients really value the Evidence Maps we develop for them. But we do a lot more for clients than just develop Maps. The enhanced Evidence Mapper platform can now be used to upload, deduplicate and double screen thousands of abstracts as part of a literature review, with the option to create an Evidence Map

from the publications that have been included in the review.

The new platform allows Project Managers and Screening Managers to:

- Upload content from .ris, .nbib, .json files, .csv spreadsheets and manually, or import from another project.
- Deduplicate using our in-built deduper, which has proven [excellent accuracy](#), saving you time.
- Allocate abstracts to one or multiple screeners and track screening progress.
- Review screening decisions and reconcile differences.
- See a summary of the flow of literature and automatically upload included abstracts into an Evidence Map.

Evidence Mapper

Clients

Tags

Projects

Scanner (duplicates and locations)

Restore backup

Dashboard

Logout

Mental health benefits of chocolate\_59 – Screening – Manual Screening

View Project Homepage

Display all Papers

Search/Filter Papers

Previous Paper

16 of 73

Next Paper

Fullscreen Mode

Jump to last viewed paper

Text Search

chocolate

Where would you like to search for the term?

☒ Title
 ☐ Author
 ☐ Abstract
 ☐ Screening Notes

Paper num

My Decision

All

Screening Status

All

Final Decision

All

Order by

Title

Ascending/Descending

☐ Ascending
 ☐ Descending

☐ Limit to my allocated papers 24-365

Clear Filters

Search

Paper 93 (added: 18-03-2024 11:32)

Full citation

Zhong GC Hu TY Yang PF Peng Y Wu JJ Sun WP Cheng L Wang CR. (2021). "Chocolate consumption and all-cause and cause-specific mortality in a US population: a post hoc analysis of the PLCO cancer screening trial." Aging. vol. 13.

Title

Chocolate consumption and all-cause and cause-specific mortality in a US population: a post hoc analysis of the PLCO cancer screening trial.

Abstract

Few studies with mixed results have examined the association between chocolate consumption and mortality. We aimed to examine this association in a US population. A population-based cohort of 91891 participants aged 55 to 74 years was identified. Chocolate consumption was assessed via a food frequency questionnaire. Cox regression was used to estimate risk estimates. After an average follow-up of 13.5 years, 19586 all-cause deaths were documented. Compared with no regular chocolate consumption, the maximally adjusted hazard ratios of all-cause mortality were 0.89 [95% confidence interval (CI) 0.84-0.94], 0.84 (95% CI 0.79-0.90), 0.86 (95% CI 0.81-0.93), and 0.87 (95% CI 0.82-0.93) for >0-0.5 servings/week, >0.5-1 serving/week, >1-2 servings/week, and >2 servings/week, respectively (P(trend) = 0.009). A somewhat stronger inverse association was observed for mortality from cardiovascular disease and Alzheimer's disease. A nonlinear dose-response pattern was found for all-cause and cardiovascular mortality (all P(nonlinearity) < 0.01), with the lowest risk observed at chocolate consumption of 0.7 servings/week and 0.6 servings/week, respectively. The favorable associations with all-cause and

Author Location

Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Department of Nephrology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China. Department of Geriatrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Link to full publication

Your Screening decision:

Notes:

Include

Exclude

Mark as Duplicate

Park

Highlight Content

Custom strings

You can also highlight custom strings related to this field...

Highlight all specific words and text strings

Configure custom strings

## Indexing abstracts within an Evidence Map is an efficient way of shortlisting papers and drilling down into the evidence

The Evidence Mapper platform allows subscribers to index each publication to a number of general or bespoke fields.

*"Once all the papers are indexed, it is easy to drill down into the evidence."*

We usually share the Map with the client and agree the systematic strategy for shortlisting publications for inclusion in the full literature review, knowing the number of papers on each topic. Clients can then use the Map to identify the key papers for their business development or market access work from just a few weeks into a literature review project, while you carry on with data extraction and report writing.

Copyright © 2024 Crystallise Ltd

4

www.crystallise.com

Evidence Mapper

[Clients](#)
[Tags](#)
[Projects](#)
[Scanner \(duplicates and locations\)](#)
[Restore backup](#)

[Dashboard](#)
[Logout](#)

Step 1:  
Map details

Step 2:  
Select fields

Step 3:  
Pages

Step 4:  
Select Papers

Step 5:  
Apply Indexers

Step 6:  
Tag papers

Step 7:  
Publish Map

Mental health benefits of chocolate\_59 – Map – Tag Papers

Offline

View Map

View Project Homepage

Continue to Publish Map

Display all Papers

Search/Filter Papers

Previous Paper

6 of 33

Next Paper

Fullscreen Mode

Jump to last viewed paper

Paper 20 (added: 18-03-2024 11:32)

Remove paper

Unpublished

Full citation

Desideri G Kwik-Uribe C Grassi D Necozione S Ghiadoni L Mastroiacovo D Raffaele A Ferri I Bacale R Leclercq MC Marini C Ferri C. (2012). "Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the CocoaCognition, and Aging (CoCoA) study." *Hypertension* (Dallas, Tex.: 1979), vol. 60.

Title

Benefits in cognitive function, blood pressure, and insulin resistance through cocoa flavanol consumption in elderly subjects with mild cognitive impairment: the CocoaCognition, and Aging (CoCoA) study.

Abstract

Abstract visible to clients

Flavanol consumption is favorably associated with cognitive function. We tested the hypothesis that dietary flavanols might improve cognitive function in subjects with mild cognitive impairment. We conducted a double-blind, parallel arm study in 90 elderly individuals with mild cognitive impairment randomized to consume once daily for 8 weeks a drink containing 990 mg (high flavanols), 520 mg (intermediate flavanols), or 45 mg (low flavanols) of cocoa flavanols per day. Cognitive function was assessed by Mini Mental State Examination, Trail Making Test A and B, and verbal fluency test. At the end of the follow-up period, Mini Mental State Examination was similar in the 3 treatment groups (P=0.13). The time required to complete Trail Making Test A and Trail Making Test B was significantly (P<0.05) lower in subjects assigned to high flavanols (38.10±0.94 and 104.10±28.73 seconds, respectively) and intermediate flavanols (40.20±11.35 and 115.97±28.35 seconds, respectively) in comparison with those assigned to low flavanols (52.60±7.97).

Author Location

University of L'Aquila, Department of Life, Health, and Environmental Sciences, Viale S Salvatore, Delta 6 Medicina, 67100 Coppito, L'Aquila, Italy. giovambattista.desideri@cc.univaq.it

Link to full publication

Notes

Abstract ID From Source

Fields:

Disease

Add New Tags

Highlight Content

Manage tags and groups

Search tags...

Name (ascending)

Search Tags

Filter?	Tag	Relevant tag?	Suggested by Indexer	On Map?	Outside Map?	Tag papers with tag
	Cognitive dysfunction					
	Hypertension					
	Insulin Resistance					
	Mild Cognitive Impairment					
	Alzheimer Disease					
	Anxiety					
	Arrhythmias, Cardiac					
	Atherosclerosis					
	Atrial Fibrillation					
	Bacterial Infections					
	Bacterial pneumonia					
	Cancer					

The new Evidence Mapper platform allows you to:

- Use our in-built indexers to suggest relevant tags based on our pre-defined tag sets or your own list, saving indexing time.
- Index content to as many fields as you need, using our text highlighter to help identify relevant tags.
- Upload documents, spreadsheets, slide decks and other resources to keep all the materials for the project in one easily-accessible location.

Copyright © 2024 Crystallise Ltd

5

www.crystallise.com

## We still offer bespoke Evidence Maps for clients who don't have the resources to develop their own

Many of our clients in pharmaceutical and biotech companies don't have the time to develop their own Maps. We are happy to include an Evidence Map as an interim deliverable as part of a systematic or targeted literature review, or as a key deliverable in a Rapid Review.

*"Our clients really appreciate the Evidence Maps we develop for them. One Pharma client has asked us to produce more than 30 Maps so far."*

Maps can be quickly updated, either to a planned timetable or as key new evidence is published, and the rapid development time, typically just 4 to 6 weeks from starting the project, means that clients can always be up-to-date with the latest research. We have developed Evidence Maps for clients from the top 10 largest pharmaceutical companies down to small start-ups, and most of our clients come back for more.

If you'd like to arrange a call so we can show you how to use the new site, please email [evidencemap@crystallise.com](mailto:evidencemap@crystallise.com)

Alternatively, you can try the new site out for free [here](#).

## Crystallise's insights & expertise

At Crystallise, we focus on synthesising and presenting evidence in a way that provides strategic support and medical insight for our clients. Our [Evidence Mapper platform](#) is ideal for collating a wide body of evidence so clients can drill down to find the studies they need for each location and topic. If you would like to hear more about this or our many other areas of research, please feel free to reach out.

---

### References:

1. Schlander, M., Hernandez-Villafuerte, K., Cheng, CY. *et al.* How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. *PharmacoEconomics* 39, 1243–1269 (2021). <https://doi.org/10.1007/s40273-021-01065-y>



# Crystallise

*Crystallise Ltd*

---

Follow us:



Email: [contact@crystallise.com](mailto:contact@crystallise.com)

Website: [www.crystallise.com](http://www.crystallise.com)